Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TTPA | P49638 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3943626 | 0.86 | — | — | |
| SCHEMBL19910935 | 0.82 | PTGS1 (0.43) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL3941352 | 0.77 | NR1I2 (0.40) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL3933202 | 0.77 | PTGS1 (0.64) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL13979807 | 0.77 | CYP3A4 (0.60) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL3035038 | 0.77 | CYP3A4 (0.60) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL3935483 | 0.75 | TTPA (0.38) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL13805561 | 0.74 | ALDH1A1 (0.31) | — | |
| SCHEMBL19910941 | 0.73 | PTGS1 (0.37) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL19899579 | 0.72 | MEN1 (0.42) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306055-A1 | PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS AND ANTIOXIDANTS | NIPPON SODA CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-20090306055-A1 | PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS AND ANTIOXIDANTS | NIPPON SODA CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-7553837-B2 | Phenylazole compounds production process and antioxidants | NIPPON SODA CO., LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553837-B2 | Phenylazole compounds production process and antioxidants | NIPPON SODA CO., LTD. (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20060247228-A1 | Phenylazole compounds production process and antioxidants | NIPPON SODA CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20060189673-A1 | Phenylazole compound, production process therefor and antioxidant | NIPPON SODA CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1650206-A1 | PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS, AND ANTIOXIDANTS | NIPPON SODA CO., LTD. (JP) | 2006-04-26 | — | — | EP | disclosed |
| EP-1614688-A1 | PHENYLAZOLE COMPOUND, PRODUCTION PROCESS, AND ANTIOXIDANT DRUG | NIPPON SODA CO., LTD. (JP) | 2006-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306055-A1 | PHENYLAZOLE COMPOUNDS, PRODUCTION PROCESS AND ANTIOXIDANTS | NOX1, CBR1, AOX1 | PTGS1 426/4885PTGS2 1767/4885CYP1A2 519/4885 |
| US-20060247228-A1 | Phenylazole compounds production process and antioxidants | CBR1, CBR3, NOX3 | PTGS1 725/4885PTGS2 1450/4885CYP1A2 345/4885 |
| US-20060189673-A1 | Phenylazole compound, production process therefor and antioxidant | CBR3, CYP4F11, CBR1 | PTGS1 368/4885PTGS2 680/4885CYP1A2 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.